Foldax is engages in synthetic heart valve development to deliver non-thrombogenic aortic and mitral valves at dramatically lower cost. Founded in 2013, Foldax is backed by investors that include Caltech – California Institute of Technology, Kairos Ventures, MemorialCare Innovation Fund, BioStar Ventures, and Sayan Bioventures and is headquartered in Salt Lake City.